- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Biochemistry Research International
Volume 2012 (2012), Article ID 714074, 12 pages
Overexpression of PGC-1α Increases Fatty Acid Oxidative Capacity of Human Skeletal Muscle Cells
1Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, P.O. Box 1068 Blindern, N-0316 Oslo, Norway
2AstraZeneca Reseach and Development, SE-43185 Mölndal, Sweden
3Boden Institute of Obesity, Nutrition and Exercise, University of Sydney, Sydney, NSW 2006, Australia
Received 15 April 2011; Accepted 29 June 2011
Academic Editor: Paul Denny
Copyright © 2012 Nataša Nikolić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We investigated the effects of PGC-1α (peroxisome proliferator-activated receptor γ coactivator-1α) overexpression on the oxidative capacity of human skeletal muscle cells ex vivo. PGC-1α overexpression increased the oxidation rate of palmitic acid and mRNA expression of genes regulating lipid metabolism, mitochondrial biogenesis, and function in human myotubes. Basal and insulin-stimulated deoxyglucose uptake were decreased, possibly due to upregulation of PDK4 mRNA. Expression of fast fiber-type gene marker (MHCIIa) was decreased. Compared to skeletal muscle in vivo, PGC-1α overexpression increased expression of several genes, which were downregulated during the process of cell isolation and culturing. In conclusion, PGC-1α overexpression increased oxidative capacity of cultured myotubes by improving lipid metabolism, increasing expression of genes involved in regulation of mitochondrial function and biogenesis, and decreasing expression of MHCIIa. These results suggest that therapies aimed at increasing PGC-1α expression may have utility in treatment of obesity and obesity-related diseases.
The genesis of obesity is multifactorial. However, there is evidence that reduced energy expenditure and in particular reduced capacity to utilise fat for metabolic fuel are important factors, particularly in the weight reduced state  PGC-1α (peroxisome proliferator-activated receptor γ coactivator-1α) is a transcriptional coactivator initially isolated from brown adipose tissue , but now known to be abundant in many metabolically active tissues, such as skeletal muscle, liver, heart, and brain, where PGC-1α plays a major role in transduction of nutritional and physiological stimuli to transcriptional metabolic and contractile responses [2, 3].
Among many transcription factors coactivated by PGC-1α are nuclear respiratory factors (NRF1/2) , myocyte enhancer factor-2 (MEF2) , and several members of nuclear hormone receptors, including peroxisome proliferator-activated receptor (PPAR) subtypes—a family of lipid activated nuclear hormone receptors that play a key role in mediating adaptive regulation of muscle fatty acid oxidation . The most common function of PGC-1α across tissues is regulation of mitochondrial physiology, but in addition, this family of coactivators controls separate, tissue-specific biological programs. In liver, expression of PGC-1α is strongly induced by fasting and stimulates hepatic gluconeogenesis and ketogenesis [6, 7]; in heart, it is a powerful stimulant of mitochondrial gene expression and biogenesis , while PGC-1α deficiency in brain has been shown to lead to behavioral abnormalities associated with axonal degeneration .
In skeletal muscle, PGC-1α is powerfully induced in conditions of increased physical activity [10–15], when ATP demand is high and induction of mitochondrial oxidative function becomes essential in order to adapt and maintain whole body energy balance. Enhancement of mitochondrial function and biogenesis occur through PGC-1α coactivation of nuclear respiratory factor (NRF) , and regulation of genes involved in oxidative phosphorylation is mediated through interactions with estrogen-related receptor α (ERRα) . In addition, adaptation to increased contractile activity involves conversion from type II (fast twitch) to type I (slow twitch) fibers , a process also shown to be driven by PGC-1α in transgenic animals , while muscle-specific knock out of PGC-1α in animals has been shown to lead to conversion from type I to type II muscle fibers, exercise intolerance, decrease in mitochondrial proteins and myopathy . Also in primary skeletal muscle cells from rats, overexpression of PGC-1α has been shown to confer a switch toward a more slow myofiber phenotype . Further, overexpression of PGC-1α improved lipid utilization, insulin signaling and glucose transport in vivo animal studies [21, 22], while whole body overexpression of PGC-1α appears to have opposite effects on hepatic and muscle insulin sensitivity . In cell cultures of rodent myotubes (C2C12 and L6), overexpression of PGC-1α has been shown to increase the level of the insulin-regulated glucose transporter 4 (GLUT4) mRNA and glucose uptake .
Peroxisome proliferator-activated receptor δ (PPARδ) is coactivated by PGC-1αin vivo and in vitro, and has been linked to increased fatty acid oxidation . In addition, PPARδ, along with PGC-1α, has been identified as one of key players mediating effects of exercise at the cellular level [16, 26, 27] and suggested as a new target for the treatment of metabolic syndrome .
Cultured myotubes are a useful tool in investigating metabolic processes at cellular level, but limited in their usefulness in that they are characterized by glycolytic properties [29, 30]. PGC-1α has been referred to as “master regulator” of the coordination of mitochondrial biogenesis, mainly because increase in PGC-1α has been shown to activate transcription factors that switch muscle cells towards oxidative metabolism [31–33]. However, significant reduction of PGC-1α levels in muscle cell cultures compared to in vivo muscle extracts has been reported in chicken , and the role of PGC-1α in metabolic processes in skeletal muscle in vitro has previously been highlighted using adenoviral overexpression in cell cultures , but data describing metabolic effects of PGC-1α overexpression in primary human skeletal muscle cells are limited .
The aim of the present work was to study whether overexpression of PGC-1α in cultured human skeletal muscle cells from healthy individuals would increase the oxidative capacity of the cells, promote fiber type conversion, and increase expression of genes involved in mitochondrial biogenesis and function. Moreover, we wanted to compare cultured myotubes to skeletal muscle in vivo. Finally, a possible interplay between PGC-1α overexpression and pharmacological activation of PPARδ on fatty acid oxidation and expression of key genes in lipid metabolism was studied.
2. Materials and Methods
DMEM-Glutamax, FCS, Ultroser G, penicillin-streptomycin-amphotericin B, and trypsin-EDTA were obtained from Life Technology (Paisley, UK). Skeletal Muscle Growth Medium Bullet Kit was obtained from Clonetics (BioWittaker, Verviers, Belgium). [3H]palmitic acid (2.0 GBq/mmol) and 2-deoxy-D-[3H]glucose (222 GBq/mmol) were purchased from Dupont NEN Life Science Products (Boston, MA, USA). Palmitic acid, BSA (essentially fatty acid-free), Cytochalasin B, and extracellular matrix gel were purchased from Sigma Chemicals (St Louis, MO, USA). Insulin Actrapid was from Novo Nordisk (Bagsvaerd, Denmark). RNeasy Mini kit and RNase-free DNase were purchased from Qiagen Sciences (Oslo, Norway). Primers were purchased from Invitrogen (Oslo, Norway). High capacity cDNA archive kit, SYBR Green, TaqMan reverse-transcription reagents kit, TaqMan Universal PCR Master Mix and micro fluidic cards were purchased from Applied Biosystems (Warrington, UK). Protein assay kit was purchased from BioRad (Copenhagen, Denmark). All other chemicals used were of standard commercial high purity quality.
2.2. Human Skeletal Muscle Biopsies and Cell Cultures
Muscle biopsy samples of the musculus obliquus internus abdominis or vastus lateralis were taken from seven healthy volunteers, and a cell bank of satellite cells was established. The biopsies were obtained with informed consent and approval by the National Committee for Research Ethics (Oslo, Norway). Muscle cell cultures free of fibroblasts were established by the method of Henry et al. . Briefly, muscle tissue was dissected in Ham’s F-10 medium at 4°C and dissociated by three successive treatments with 0.05% trypsin/EDTA, and satellite cells were resuspended in skeletal muscle cell growth medium 2% FCS, 50 U/mL penicillin, 50 μg streptomycin, 1.25 μg/mL amphotericin B, and no added insulin. The cells from each donor were grown separately on culture wells or flasks coated with extracellular matrix gel . After 1-2 weeks, at ~80% confluence, growth medium was replaced by DMEM with 2% FCS, 50 U/mL penicillin, 50 μg/mL streptomycin, 1.25 μg/mL amphotericin B, and 25 pM insulin to induce differentiation of myoblasts into multinucleated myotubes. The cells were cultured in a humidified 5% CO2 atmosphere at 37°C, and medium was changed every 2-3 days. All myotube cultures were used for analysis on day 7 or 8 after the onset of differentiation.
2.3. Transient Retroviral Vector Production
The three retroviral constructs used in this study were pBABE (empty vector), pBABE-hPGC-1α, and pBABE-zsGreen (positive control for infection efficacy). 293T/17 cells were seeded 8 h prior to transfection at a density of cells per 100 mm culture dishes in 15 mL of DMEM with 2 mM L-glutamine and 10% foetal calf serum (FCS). Transfection was performed using ProFection Mammalian Transfection System (Promega Biotech, Sweden). DNA mixture was prepared by diluting following amounts of plasmids: 16 μg genome, 16 μg pVPack and 8 μg pME-VSV-G to 438 μL distilled water per 100 mm culture dish. Fifteen min prior to transfection, 65.5 μL CaCl2 and 500 μL HEPES were added to DNA mixture, and 1 mL of DNA/CaCl2/HEPES was then added to each culture dish. The cells were allowed to incubate at a humidified 5% CO2 atmosphere at 37°C for 24 h, when medium was replaced with 10 mL fresh prewarmed DMEM with 10 mM sodium butyrate (per 100 mm culture dish) and incubated at 5% CO2 atmosphere and 37°C for an additional 6 h. The medium was then removed, and fresh medium without sodium butyrate was added, and the cells incubated for another 16 h. The medium was collected and the supernatant filtered through 0.45 μm pore filter and used directly to infect cultured myoblasts. The described protocol was applied identically for production of all three retroviral constructs: pBABE, pBABE-hPGC-1α, and pBABE-zsGreeen.
2.4. Retroviral Infection of Cultured Human Myoblasts
Infection of cultured myoblasts with 100% viral supernatant in the presence of 2 μg/mL polybrene for 24 h gave highest infection efficiency in pilot experiments, and these conditions were chosen for further infections. Cultured myoblasts were seeded at a density of 8000–14000 (depending on growth rate) cells/cm2 and infected 1-2 days after seeding with 2 mL (per well in a 6-well plate) 100% retroviral supernatant containing either pBABE (empty vector), PGC-1α or pBABE-zsGreen (positive control) in the presence of 2 μg/mL polybrene, and incubated for 24 h. Thereafter, the virus-containing medium was replaced by Clonetics SkGM-BulletKit without insulin. The cells were allowed to reach ~80% confluence, when medium was replaced by DMEM with 2% FCS, 50 U/mL penicillin, 50 μg/mL streptomycin, 1.25 μg/mL amphotericin B and 25 pM insulin to induce the differentiation of myoblasts into multinucleated myotubes. All experiments on myotube cultures were performed on day 7 or 8 after the onset of differentiation. Pretreatments with GW501516 or control (DMSO) were performed 48 h prior to experiments.
2.5. Palmitic Acid Uptake and Oxidation
Myotubes grown on six-well plates were rinsed with 3 mL of PBS and exposed to [3H]palmitic acid (50 μM, 0.5 μCi/mL in PBS with 0.5% fatty acid free albumin (BSA) 1 mL/well), in a humidified 5% CO2 atmosphere at 37°C. After 30 or 60 min of incubation, myotubes were placed on ice, and the incubation medium was transferred to new vials and assayed for labeled acid-soluble metabolites (ASMs) as previously described . Briefly, incubation medium was precipitated by addition of 150 μL of 20% BSA and 80 μL of 1 M perchloric acid and centrifuged twice (20000 g, 5 min, 4°C). The supernatant was counted for radioactivity by liquid scintillation. No-cell controls were included. Cells were washed twice with PBS and lysed in 0.3 mL M-PER (Mammalian Protein Extraction Reagent, Thermo Scientific). Cell-associated radioactivity was measured by liquid scintillation. PA uptake was calculated as the sum of ASM (corrected for no cell control) in the medium and the cell-associated radioactivity in the cells. Protein content was determined using the BCA assay (Pierce).
2.6. Deoxyglucose Transport and Glycogen Synthesis
Myotubes were incubated for 60 min in serum-free DMEM with 5.5 mM glucose, with or without 10 μM cytochalasin B at 37°C. Deoxyglucose uptake was measured for 15 min in the presence of 10 μM unlabeled deoxyglucose and (1 μCi/mL) 2-deoxy-D-[3H]glucose in glucose uptake buffer (140 mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2, pH 7.4). After incubation, the cells were washed three times with ice-cold PBS and lysed with 0.3 mL M-PER, and the radioactivity was counted by liquid scintillation. Noncarrier mediated glucose transport was determined in the presence of cytochalasin B (10 μM) and subtracted from all values. For measurement of glycogen synthesis, myotubes were incubated for 2 h (37°C, 5% CO2) in serum-free DMEM (±100 nM insulin), before adding DMEM with 2 μCi/mL D-[U-14C]-glucose in the presence or absence of 100 nM insulin for 60 min. After 60 min, the cells were washed three times with ice-cold PBS and lysed with 1 M NaOH. Synthesised glycogen was measured as described . Glycogen synthesis increased linearly within 4 h after insulin stimulation and is presented as nmol·mg cell protein−1·h−1. The protein content of each sample was determined according to Bradford using BSA as the reference protein.
2.7. RNA Isolation and Analysis of Gene Expression by Quantitative Real-Time PCR
Human skeletal muscle biopsies and myotubes grown in 6-well plates were lysed in 1 mL Trizole reagent (Invitrogen, Oslo, Norway) according to the supplier’s total RNA isolation protocol. The isolated RNA was dissolved in RNase-free water, and concentration was determined by spectrophotometric measurement at 260 nm. All samples were also electrophoresed in 1% agarose gel to assess integrity of ribosomal bands.
Total RNA from above was treated with DNase (DNA-free, Ambion) to remove contaminating genomic DNA before cDNA synthesis. Shortly, 0.1 volume of 10 times DNase buffer, 4–6 units of DNase and water up to 30 μL was added to each sample. Samples were incubated at 37°C for 40–45 min. DNase inactivation reagent was added to each sample and removed by centrifugation after 2 min incubation at room temperature.
First strand cDNA synthesis was performed with SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Oslo, Norway) according to supplier protocol. 1 μg of DNase treated total RNA was used in each synthesis. Priming of synthesis was accomplished with Oligo(dT)12-18. For each synthesis reaction a negative control with no enzyme was set up. Obtained cDNA was used for relative quantification on Applied Biosystems 7700. Quantitative real-time PCR was carried out using either TaqMan Universal PCR Master Mix or SYBR Green PCR Master Mix (both from Applied BioSystems) in 25 μL reactions run in triplicates. Template for the PCR was first strand cDNA from above (amount equivalent of 5–25 ng total RNA). Following forward and reverse primers and in case of TaqMan Universal PCR Master Mix, labelled probes, specific for the different genes, were used at concentrations of 200 nM and 400 nM, respectively: CD36: F: GGGAAAGTCACTGCGAC ATGA, R: GAACTGCAATACCTGGCTTTTCTC, Probe: TACAGATGCAGCCTCATTTC CACCTTTTGT; CPT1b: F: GCGCTGGAGGTGG CTTT, R: TCGTGTTCTCGCCTGCAAT, Probe: AAACTCCATAGCCATCATCTGCTAC AGGGC; MCAD: F: TACTTGTAGAGCACCAAGCAATATCA, R: TGCTCTCTGGTAA CTCATTCTAGCTAGT, Probe: CAACTTTCATTGCCATTTCAGCCAGCATA; ATGL: F: CGCACCTGTGCCTTAATCTTC, R: GCTGCAAAGTTCTCAGGAGTAAAG; HSL: F: C AGAAGATGTCGGAGCCCATA, R: GGCCAGTGCTGCTTCAGAC; PPARα: F: CTCT CAGGAAAGGCCAGTAACAA, R: TGGCCACCAGCGTCTTCT, Probe: CACCTTTTG TCATACATGATATGGAGACACTGTGT; PPARγ: F: GTCACGGAACACGTGCAGC, R: GCAGGAGCGGGTGAAGACT; PPARδ: F: TGCGGCAACTGGTCACC, R: TCTCGGTT TCGGTCTTCTTGA; cytochrome C: F: CTGCCAACAACGGAGCATT, R: CGTGAGCA GGGAGAAGACGTA, Probe: CACCATGCCTAGCTCGCACGATGTAG; COXIV: F: CC GCGCTCGTTATCATGTG, R: CACCCACTCTTTGTCAAAGCTTT, Probe: CACTATGT GTACGGCCCCCTCCCG; SOD2: F: GCTTGTCCAAATCAGGATCCA, R: GCGTGCTC CCACACATCA; SOD3: F: GGCCTCCATTTGTACCGAAA, R: CGGGAGTCTCAGGGC TTATG; UCP-2: F: TGAGCTGGTGACCTATGACCTCAT, R: AGTGGCAAGGGAGGTC ATCTGT, Probe: AAGGATGCCCTCCTGAAAGCCAACCT; UCP-3: F: CTGCTGGACT ATCACCTGCTCA, R: CCACCACTGTGGCACAGAAG, Probe: ACAACTTCCCCTGCC-ACTTTGTCTCTGC; ERRα: F: GAGAGGAGTATGTTCTACTAAAGGCCTT, R: GCCTC GTGCAGGAGCTTCT, Probe: TCGGCTCATCTTCGATGTGCACAGAGTC, NRF1: F: C ATGCGTTGAGCTACTGACAAAC. R: AGTCCAGCAGGGAGAGTTCTGT, mtTFA: F: GCTGAAAGATTCCAAGAAGCTAAGG, R: TTCAGAGTCAGACAGATTTTTTTCCAG-TT; MHCI: F: CCAGACTGTGTCTGCTCTCTTCAG, R: CAGGACAAGCTCATGCTCC AT, MHCIIa: F: AAGGTCGGCAATGAGTATGTCA, R: CAACCATCCACAGGAACAT CTTC.
For all PCR reactions, two types of negative controls were used. As control for possible amplification of remaining genomic DNA, no enzyme controls from cDNA synthesis were set up for all primer-probe sets. The other negative control was with no template included. All signals were normalized to housekeeping gene 36B4. Samples were run on ABI Prism 7700 using the default program: first, two steps with 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. When SYBR Green PCR Master Mix was used, PCR product from one well in each triplicate was loaded on an 2.5% NuSieve Agarose (BioWhittaker Molecular Applications) gel to confirm one band in the correct size.
Aliquots of 20 μg cell protein from total cell lysates prepared in Laemmli buffer were electrophoretically separated on NuPage 4–12% (w/v) Bis-Tris gel (Invitrogen), followed by immunoblotting with specific antibodies (Anti OxPhos Complex IV, mouse monoclonal 20E8, Cat. A-21248 from Molecular Probes, Anti Cytochrome C, mouse monoclonal 7H8. 2C12, Cat. 556433 from BD Pharmingen). Immunoreactive bands were visualized with ECL Western blotting detection reagents (Amersham International).
2.9. Statistical Analyses
All statistical analyses were performed using GraphPad Prism 4.0 for Windows (GraphPad Software Inc., San Diego, CA). Two-tailed paired t-tests were performed to determine the effects of PGC-1α overexpression. All values in figures are presented as mean ± SEM. Statistical significance was set at . For gene analysis, a fold change ≥2 or ≤0.5 was considered an increase or a decrease in expression level, respectively.
3.1. Retroviral Overexpression of PGC-1α in Cultured Human Skeletal Muscle Cells
To determine whether experimental alterations in PGC-1α expression would affect oxidative capacity of cultured human skeletal muscle cells, myoblasts were infected 48 h after seeding. Images of myoblasts taken 48 h after infection with positive control virus pBABE-zsGreen are shown in Figure 1. No morphological changes compared to uninfected control cells were observed in cells infected with either empty vector or PGC-1α (data not shown). PGC-1α mRNA expression in cells infected with PGC-1α increased 150–200-fold compared to cells infected with empty control vector (Figure 2(a)). In skeletal muscle biopsies, PGC-1α mRNA expression was about 35-fold higher than in differentiated cultured skeletal muscle cells (Figure 2(b)), thus PGC-1α infection restored the reduction in PGC-1α mRNA expression observed during cell culturing.
3.2. PGC-1α Overexpression Increased Palmitic Acid Oxidation
Oxidation of palmitic acid (PA) was measured 7-8 days after the onset of differentiation. Rate of PA oxidation, measured as acid soluble metabolites (ASM), was significantly increased by 71% () in cells overexpressing PGC-1α compared to control cells infected with empty vector (Figure 3(a)). PA oxidation rate in uninfected cells (4.3 ± 0.7 nmol/mg/h) did not differ from the cells infected with empty control vector (4.0 ± 0.7 nmol/mg/h), showing that the observed increase in fatty acid oxidation rate (6.8 ± 1.4 nmol/mg/h) was due to overexpression of PGC-1α. Overexpression of PGC-1α did not affect the uptake of PA compared to cells infected with empty control vector (Figure 3(b)).
3.3. PGC-1α Overexpression Increased mRNA Expression of Genes Important for Lipid Metabolism, Mitochondrial Biogenesis, and Function
To identify potential mechanisms responsible for the observed effects of PGC-1α overexpression on PA oxidation, mRNA expressions of selected genes encoding key enzymes regulating fatty acid transport, storage and oxidation pathways and mitochondrial function were examined (Figure 4).
Among genes involved in lipid metabolism, PGC-1α-mediated increase in mRNA expression was most distinct for MCAD (medium chain acyl-coenzyme A dehydrogenase) (7.4-fold), but also PPARα was increased 3.2-fold, and CPT1b (carnitine palmitoyltransferase 1b) and HSL (hormone sensitive lipase) both 2.7-fold (Figure 4(a)). In comparison, mean mRNA expression levels of MCAD, PPARα and CPT1b in skeletal muscle biopsies were 24-, 22.5- and 191-fold higher than in cultured cells, respectively (Table 1). Levels of PPARγ, PPARδ, and fatty acid transport protein CD36 were not affected by PGC-1α overexpression in human myotubes (Figure 4(a)).
Overexpression of PGC-1α resulted in a marked increase in mRNA levels of several important components of the respiratory chain: cytochrome C (4.5-fold), COX IV (cytochrome C oxidase IV) (3.6-fold), SOD-2 (superoxide dismutase-2) (3.6-fold), and SOD-3 (2.9-fold) (Figure 4(b)). Protein levels of cytochrome C and COXIV were also increased in cells overexpressing PGC-1α compared to both cells infected with empty control vector and uninfected cells (Figure 4(c)). Two important genes involved in regulation of mitochondrial biogenesis, ERRα (estrogen related receptor α) and mtTFA (mitochondrial transcription factor A), were also noticeably increased in PGC-1α cells, by 3.6-fold and 2.2-fold, respectively (Figure 4(b)). Expressions of NRF1 (nuclear respiratory factor 1) and uncoupling proteins UCP-2 and UCP-3 did not appear to be affected by PGC-1α overexpression (Figure 5(b)). In biopsies, mean mRNA expression levels of cytochrome C, COX IV, and ERRα were 9.1-, 5.0-, and 7.0-fold higher than in cultured cells, respectively (Table 1).
3.4. PPARδ Stimulation Potentiated PGC-1α-Induced Palmitic Acid Oxidation
We further examined whether effects of PGC-1α overexpression on fatty acid metabolism in human myotubes could be potentiated by simultaneously stimulating PPARδ, a known target of PGC-1α coactivation . We used a highly potent and selective PPARδ agonist, GW501516 , which we have previously shown to increase the rate of oleic acid oxidation in cultured human skeletal muscle cell . In myotubes overexpressing PGC-1α, 48 h of GW501516 (10 nM) treatment seemed to potentiate PA oxidation (from 7.6 ± 1.7 nmol/mg/h to 18.2 ± 5.9 nmol/mg/h) compared to myotubes infected with empty vector (from 4.6 ± 0.1 nmol/mg/h to 9.5 ± 2.2 nmol/mg/h) (Figure 5(a)). At the mRNA level, there was an additive effect of PPARδ activation by GW501516 on PGC-1α-induced CPT1b expression (Figure 5(b)). Expression of genes involved in mitochondrial function (cytochrome C, COXIV, ERRα, UCP-2, and UCP-3) was not affected by GW501516 treatment (data not shown).
3.5. Overexpression of PGC-1α Decreased Glucose Transport
To further assess metabolic effects of PGC-1α overexpression, glucose transport and glycogen synthesis were measured. In cells overexpressing PGC-1α, deoxyglucose uptake was decreased compared to cells infected with empty vector (Figure 6(a)). The rate of deoxyglucose transport was unchanged in cells infected with empty control vector compared to uninfected cells (31.7 ± 8.9 nmol/mg/min and 33.3 ± 9.3 nmol/mg/min, resp.), while it decreased to 15.6 ± 8.9 nmol/mg/min in myotubes overexpressing PGC-1α. Insulin increased glucose uptake by about 25% both in control cells and in cells overexpressing PGC-1α (Figure 6(a)). Glycogen synthesis was also induced by insulin, but neither basal nor insulin-induced glycogen synthesis were affected by PGC-1α overexpression (Figure 6(b)). The level of GLUT1 mRNA was unaffected by PGC-1α expression, while GLUT4 mRNA level increased 6-fold (Figure 6(c)). PDK4 (pyruvate dehydrogenase kinase 4) was also markedly increased in PGC-1α infected cells (6-fold) (Figure 6(c)).
3.6. PGC-1α Overexpression Reduced Expression of Fiber Type IIa Gene Marker
To assess the role of PGC-1α on fiber-type gene markers in myotubes, we further investigated expression of genes specifically enriched in either type I (slow) fibers (MHCI) or type IIa (fast) fibers (MHCIIa). Expression of MHCIIa mRNA was significantly decreased in cells overexpressing PGC-1α () (Figure 7), while the increase in MHCI mRNA level was not significant. Thus, the MHCI/MHCIIa mRNA ratio was nearly doubled in cells overexpressing PGC-1α compared to control cells infected with empty vector (from 3.4 to 5.9, resp.).
The aim of the present study was to determine whether overexpression of the transcriptional coactivator PGC-1α would increase oxidative capacity of human skeletal muscle cells and to compare these cells to skeletal muscle in vivo. PGC-1α overexpression increased palmitic acid oxidation and expression of key genes involved in regulation of lipid metabolism: CPT1b, MCAD, PPARα and HSL, as well as genes involved in mitochondrial function and biogenesis. Compared to skeletal muscle in vivo, PGC-1α overexpression increased expression of several genes which were downregulated during the process of cell isolation and culturing. Further, our results showed that uptake of glucose in skeletal muscle cells infected with PGC-1α was decreased, while mRNA expression of PDK4 was increased, as well as mRNA level of GLUT4. Moreover, when PGC-1α was overexpressed, the ratio of the mRNA level of MHCI (a gene marker of type I, slow oxidative fiber type) to that of MHCIIa (a gene marker of glycolytic, fast-twitch skeletal muscle fibers) was increased.
Human primary myotubes retain some of the metabolic characteristics of mature skeletal muscles, but are generally limited, in vitro, by their low oxidative capacity [29, 30]. This is possibly due to downregulation of PGC-1α and lack of proliferation of mitochondria in the absence of necessary cell environmental signals. In the present study, the rate of palmitic acid oxidation was significantly increased when PGC-1α was overexpressed; an effect which cannot be attributed to increased uptake of palmitic acid from the medium, as this was unchanged. The increase in the oxidation rate of palmitic acid was accompanied by enhanced expression of key genes regulating lipid oxidation: CPT1b, MCAD, and PPARα. ATGL has been shown to be upregulated in human skeletal muscle after exercise , along with increased utilization of intramyocellular triacylglycerols, while protein levels of HSL remain unchanged [42, 43]. In the present work, ATGL and HSL mRNA levels were increased by 1.6 and 2.4 fold, respectively, when PGC-1α was overexpressed. Interestingly, an in vivo study has shown that in human skeletal muscles, ATGL is expressed exclusively in type I (oxidative) fibers , so upregulation of this gene could indicate a shift toward more fiber type I-like myotubes when PGC-1α is overexpressed.
PGC-1α has been shown to increase mitochondrial biogenesis by several cellular mechanisms [10, 26, 45–47] and to improve lipid oxidation at rest and during submaximal exercise. We found several components of the respiratory chain to be increased at the mRNA level, such as cytochrome C and COXIV, and increase in protein levels of these two components were also compared by immunoblotting (Figure 4(c)). mtTFA, a transcription factor downstream of PGC-1α, critical for mtDNA replication , was also increased, suggesting that biogenesis of mitochondria might be increased when PGC-1α is overexpressed in cultured human myotubes. Furthermore, both superoxide dismutases (SODs) investigated in the present study, the mitochondrial SOD-2 and the extracellular SOD-3, were upregulated at mRNA level when PGC-1α was overexpressed. SODs catalyze the reduction of superoxide anions into hydrogen peroxide and oxygen, contributing as such to antioxidant defense of nearly all cells exposed to oxygen, and recent findings have shown that SOD-2 overexpression in mice preserves myoblast mitochondrial mass and function with aging .
Recently, PGC-1α and PPARδ have been identified as key players in exercise-signaling cascade leading to mitochondrial biogenesis [16, 27]. In the present work, we also wanted to investigate whether some of the effects of PGC-1α overexpression on lipid metabolism and mitochondrial function could be potentiated by simultaneously activating endogenous PPARδ with a selective agonist GW501516. PPARδ stimulation appeared to enhance PGC-1α-mediated increase in palmitic acid oxidation and CPT1b expression. The effect of PPARδ activation on expression of CPT1b is in agreement with results from in vitro studies using mouse myotubes . In our study, we could not see any effect of PPARδ activation on the expression of genes in mitochondrial function, which is in contrast to what has been reported in the muscle-specific VP16-PPARδ transgenic mice but not in the transgenic mice overexpressing the native PPARδ protein , and in agreement with results found in C2C12 cells (skeletal mouse muscle cells) , PPARδ activation did not promote mitochondrial gene expression, even though it increased fatty acid oxidation, since none of the genes in electron transport chain were increased by PPARδ stimulation.
Both PGC-1α and GLUT4 are often deficient in cultured skeletal muscle cells [24, 34], and in primary human myotubes, basal glucose uptake is generally mediated by other glucose transporters, such as GLUT1 and GLUT3 [51, 52]. In the present work, basal glucose uptake was significantly decreased in human myotubes overexpressing PGC-1α, while GLUT1 mRNA expression was unchanged. A previous study with adenoviral overexpression of PGC-1α in C2C12 and L6 cells showed total restoration of GLUT4 mRNA levels to those observed in vivo, with a 3-fold increase in insulin-stimulated glucose transport . In our study, overexpression of PGC-1α caused increased GLUT4 mRNA but did not increase insulin-stimulated glucose uptake. Inconsistencies between mRNA levels of GLUTs and functional data have been reported in human cultured skeletal muscle cells previously [53–55]. However, it is possible that the observed decrease in glucose uptake could be due to increased mRNA level of PDK4, an inhibitor of pyruvate dehydrogenase complex, which switches oxidation towards lipids.
Muscle fibre type and oxidative capacity have been linked to obesity and insulin resistance with a higher percentage of type 1 being positively related to insulin action and inversely with obesity [56, 57]. In addition it has been shown in studies with transgenic animals that PGC-1α appears to be an important factor in regulating muscle fiber type determination . In the present study, myotubes infected with retro virus coding for PGC-1α had in increased MHCI/MCHIIa ratio based on gene markers for type I and type IIa fibers respectively. To our knowledge, shift in fiber-type composition has not previously been shown in cultured human skeletal muscle cells. The fact that there is a tendency towards increased MHCI/MHCIIa ratio indicates the possibility of a more complete switching between fiber types at conditions when PGC-1α is overexpressed, also in cultured skeletal muscle cells.
In summary, in the present study, overexpression of PGC-1α in cultured human myotubes increased fatty acid oxidative capacity of the cells and increased expression of genes involved in regulation of mitochondrial function. Compared to skeletal muscle in vivo, PGC-1α overexpression increased expression of several genes, which were downregulated during the process of cell isolation and culturing. We have also shown that mRNA expression of a fast fiber-type gene marker (MHCIIa) was decreased, suggesting that PGC-1α may play a role in fiber-type regulation in human myotubes.
Conflict of Interests
None of the authors have a conflict of interests to declare.
This work was funded by the University of Oslo and AstraZeneca R&D, Sweden.
- J. C. Clapham and L. H. Storlien, “The fatty acid oxidation pathway as a therapeutic target for insulin resistance,” Expert Opinion on Therapeutic Targets, vol. 10, no. 5, pp. 749–757, 2006.
- P. Puigserver, Z. Wu, C. W. Park, et al., “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” Cell, vol. 92, no. 6, pp. 829–839, 1998.
- P. Puigserver and B. M. Spiegelman, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator,” Endocrine Reviews, vol. 24, no. 1, pp. 78–90, 2003.
- J. Lin, C. Handschin, and B. M. Spiegelman, “Metabolic control through the PGC-1 family of transcription coactivators,” Cell Metabolism, vol. 1, no. 6, pp. 361–370, 2005.
- A. J. Gilde and M. Van Bilsen, “Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle,” Acta Physiologica Scandinavica, vol. 178, no. 4, pp. 425–434, 2003.
- S. Herzig, F. Long, U. S. Jhala et al., “CREB regulates hepatic gluconeogenesis through the coactivator PGC-1,” Nature, vol. 413, pp. 179–183, 2001.
- J. Rhee, Y. Inoue, J. C. Yoon et al., “Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1): requirement for hepatocyte nuclear factor 4α in gluconeogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4012–4017, 2003.
- J. J. Lehman, P. M. Barger, A. Kovacs, et al., “Peroxisome proliferator-activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis,” Journal of Clinical Investigation, vol. 106, no. 7, pp. 847–856, 2000.
- T. C. Leone, J. J. Lehman, B. N. Finck et al., “PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis,” PLoS Biology, vol. 3, no. 4, Article ID e101, 2005.
- K. Baar, A. R. Wende, T. E. Jones et al., “Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1,” The FASEB Journal, vol. 16, no. 14, pp. 1879–1886, 2002.
- M. Goto, S. Terada, M. Kato et al., “CDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats,” Biochemical and Biophysical Research Communications, vol. 274, no. 2, pp. 350–354, 2000.
- S. Terada, M. Goto, M. Kato, et al., “Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle,” Biochemical and Biophysical Research Communications, vol. 296, no. 2, pp. 350–354, 2002.
- H. Pilegaard, B. Saltin, and P. D. Neufer, “Exercise induces transient transcriptional activation of the PGC-1α gene in human skeletal muscle,” Journal of Physiology, vol. 546, no. 3, pp. 851–858, 2003.
- I. Irrcher, P. J. Adhihetty, T. Sheehan, et al., “PPARγ coactivator-1α expression during thyroid hormone—and contractile activity-induced mitochondrial adaptations,” American Journal of Physiology, vol. 284, no. 6, pp. C1669–C1677, 2003.
- J. P. Little, A. Safdar, N. Cermak, et al., “Acute endurance exercise increases the nuclear abundance of PGC-1α in trained human skeletal muscle,” American Journal of Physiology, vol. 298, no. 4, pp. R912–R917, 2010.
- J. Lin, H. Wu, P. T. Tarr et al., “Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres,” Nature, vol. 418, no. 6899, pp. 797–801, 2002.
- V. K. Mootha, C. Handschin, D. Arlow et al., “Errα and gabpa/b specify pgc-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6570–6575, 2004.
- F. W. Booth and D. B. Thomason, “Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models,” Physiological Reviews, vol. 71, no. 2, pp. 541–585, 1991.
- C. Handschin, S. Chin, P. Li et al., “Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1α muscle-specific knock-out animals,” Journal of Biological Chemistry, vol. 282, no. 41, pp. 30014–30021, 2007.
- O. H. Mortensen, L. Frandsen, P. Schjerling, et al., “PGC-1α and PGC-1β have both similar and distinct effects on myofiber switching toward an oxidative phenotype,” American Journal of Physiology, vol. 291, no. 4, pp. E807–E816, 2006.
- C. R. Benton, G. P. Holloway, X. X. Han et al., “Increased levels of peroxisome proliferator-activated receptor gamma, coactivator 1 α (PGC-1α) improve lipid utilisation, insulin signalling and glucose transport in skeletal muscle of lean and insulin-resistant obese zucker rats,” Diabetologia, vol. 53, no. 9, pp. 2008–2019, 2010.
- C. R. Benton, J. G. Nickerson, J. Lally et al., “Modest PGC-1α overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria,” Journal of Biological Chemistry, vol. 283, no. 7, pp. 4228–4240, 2008.
- H. Liang, B. Balas, P. Tantiwong, et al., “Whole body overexpression of PGC-1α has opposite effects on hepatic and muscle insulin sensitivity,” American Journal of Physiology, vol. 296, no. 4, pp. E945–E954, 2009.
- L. F. Michael, Z. Wu, R. B. Cheatham et al., “Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 3820–3825, 2001.
- Y. X. Wang, C. H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor Δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.
- D. C. Wright, P. C. Geiger, D. H. Han, et al., “Calcium induces increases in peroxisome proliferator-activated receptor γ coactivator-1α and mitochondrial biogenesis by a pathway leading to p38 mitogen-activated protein kinase activation,” Journal of Biological Chemistry, vol. 282, no. 26, pp. 18793–18799, 2007.
- Y. X. Wang, C. L. Zhang, R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPARΔ,” PLoS Biology, vol. 2, no. 10, Article ID e294, 2004.
- S. Luquet, J. Lopez-Soriano, D. Holst et al., “Roles of peroxisome proliferator-activated receptor Δ (PPARΔ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome,” Biochimie, vol. 86, no. 11, pp. 833–837, 2004.
- V. Sarabia, L. Lam, E. Burdett, et al., “Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin,” Journal of Clinical Investigation, vol. 90, no. 4, pp. 1386–1395, 1992.
- B. Ukropcova, M. McNeil, O. Sereda et al., “Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor,” Journal of Clinical Investigation, vol. 115, no. 7, pp. 1934–1941, 2005.
- T. R. Koves, P. Li, J. An et al., “Peroxisome proliferator-activated receptor-γ co-activator 1α-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33588–33598, 2005.
- N. Gleyzer, K. Vercauteren, and R. C. Scarpulla, “Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators,” Molecular and Cellular Biology, vol. 25, no. 4, pp. 1354–1366, 2005.
- D. P. Kelly and R. C. Scarpulla, “Transcriptional regulatory circuits controlling mitochondrial biogenesis and function,” Genes and Development, vol. 18, no. 4, pp. 357–368, 2004.
- J. R. Crew, K. Falzari, and J. X. DiMario, “Muscle fiber type specific induction of slow myosin heavy chain 2 gene expression by electrical stimulation,” Experimental Cell Research, vol. 316, no. 6, pp. 1039–1049, 2010.
- L. A. Consitt, J. A. Bell, T. R. Koves et al., “Peroxisome proliferator-activated receptor-γ coactivator-1α overexpression increases lipid oxidation in myocytes from extremely obese individuals,” Diabetes, vol. 59, no. 6, pp. 1407–1415, 2010.
- R. R. Henry, L. Abrams, S. Nikoulina, et al., “Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures,” Diabetes, vol. 44, no. 8, pp. 936–946, 1995.
- M. Gaster, H. Beck-Nielsen, and H. D. Schroder, “Proliferation conditions for human satellite cells. The fractional content of satellite cells,” Acta Pathologica Microbiologica et Immunologica Scandinavica, vol. 109, no. 11, pp. 726–734, 2001.
- S. Skrede, P. Wu, and J. Bremer, “Tetradecylthioacrylic acid, a β-oxidation metabolite of tetradecylthiopropionic acid, inhibits fatty acid activation and oxidation in rat,” World Review of Nutrition and Dietetics, vol. 75, pp. 30–34, 1994.
- J. Franch, R. Aslesen, and J. Jensen, “Regulation of glycogen synthesis in rat skeletal muscle after glycogen-depleting contractile activity: effects of adrenaline on glycogen synthesis and activation of glycogen synthase and glycogen phosphorylase,” Biochemical Journal, vol. 344, part 1, pp. 231–235, 1999.
- M. L. Sznaidman, C. D. Haffner, P. R. Maloney, et al., “Novel selective small molecule agonists for peroxisome proliferator-activated receptor Δ (PPARΔ)—synthesis and biological activity,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003.
- C. C. Ciocoiu, N. Nikolic, H. H. Nguyen, et al., “Synthesis and dual PPARα/Δ agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516,” European Journal of Medicinal Chemistry, vol. 45, no. 7, pp. 3047–3055, 2010.
- T. J. Alsted, L. Nybo, M. Schweiger, et al., “Adipose triglyceride lipase in human skeletal muscle is upregulated by exercise training,” American Journal of Physiology, vol. 296, no. 3, pp. E445–E453, 2009.
- J. W. Helge, T. O. Biba, H. Galbo, et al., “Muscle triacylglycerol and hormone-sensitive lipase activity in untrained and trained human muscles,” European Journal of Applied Physiology, vol. 97, no. 5, pp. 566–572, 2006.
- J. W. Jocken, E. Smit, G. H. Goossens et al., “Adipose triglyceride lipase (ATGL) expression in human skeletal muscle is type I (oxidative) fiber specific,” Histochemistry and Cell Biology, vol. 129, no. 4, pp. 535–538, 2008.
- D. A. Hood, I. Irrcher, V. Ljubicic, et al., “Coordination of metabolic plasticity in skeletal muscle,” Journal of Experimental Biology, vol. 209, no. 12, pp. 2265–2275, 2006.
- D. A. Hood, “Invited review: contractile activity-induced mitochondrial biogenesis in skeletal muscle,” Journal of Applied Physiology, vol. 90, no. 3, pp. 1137–1157, 2001.
- M. A. Tarnopolsky, C. D. Rennie, H. A. Robertshaw, et al., “Influence of endurance exercise training and sex on intramyocellular lipid and mitochondrial ultrastructure, substrate use, and mitochondrial enzyme activity,” American Journal of Physiology, vol. 292, no. 3, pp. R1271–R1278, 2007.
- G. S. Shadel and D. A. Clayton, “Mitochondrial transcription initiation. Variation and conservation,” Journal of Biological Chemistry, vol. 268, no. 22, pp. 16083–16086, 1993.
- S. Lee, H. Van Remmen, and M. Csete, “Sod2 overexpression preserves myoblast mitochondrial mass and function, but not muscle mass with aging,” Aging Cell, vol. 8, no. 3, pp. 296–310, 2009.
- S. Kleiner, V. Nguyen-Tran, O. Bare, et al., “PPARΔ agonism activates fatty acid oxidation via PGC-1α but does not increase mitochondrial gene expression and function,” Journal of Biological Chemistry, vol. 284, no. 28, pp. 18624–18633, 2009.
- L. Al-Khalili, G. D. Cartee, and A. Krook, “Rna interference-mediated reduction in GLUT1 inhibits serum-induced glucose transport in primary human skeletal muscle cells,” Biochemical and Biophysical Research Communications, vol. 307, no. 1, pp. 127–132, 2003.
- M. Gaster, A. Handberg, A. Schurmann, et al., “GLUT11, but not GLUT8 or GLUT12, is expressed in human skeletal muscle in a fibre type-specific pattern,” Pflugers Archiv European Journal of Physiology, vol. 448, no. 1, pp. 105–113, 2004.
- E. T. Kase, G. H. Thoresen, S. Westerlund, et al., “Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals,” Diabetologia, vol. 50, no. 10, pp. 2171–2180, 2007.
- E. T. Kase, A. J. Wensaas, V. Aas et al., “Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway,” Diabetes, vol. 54, no. 4, pp. 1108–1115, 2005.
- L. L. Tortorella and P. F. Pilch, “C2C12 myocytes lack an insulin-responsive vesicular compartment despite dexamethasone-induced GLUT4 expression,” American Journal of Physiology, vol. 283, no. 3, pp. E514–E524, 2002.
- S. Lillioja, A. A. Young, C. L. Culter et al., “Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man,” Journal of Clinical Investigation, vol. 80, no. 2, pp. 415–424, 1987.
- A. D. Kriketos, D. A. Pan, S. Lillioja et al., “Interrelationships between muscle morphology, insulin action, and adiposity,” American Journal of Physiology, vol. 270, no. 6, pp. R1332–R1339, 1996.